clinical trial · NCT02949830
A Study to Evaluate Long-term Safety and Clinical Activity of Givosiran (ALN-AS1) in Patient With Acute Intermittent Porphyria (AIP)
Acute Intermittent PorphyriaGivosiran
brief summary
The purpose of this study is to determine the long-term safety, tolerability and pharmacokinetics of givosiran (ALN-AS1) in AIP patients who completed study ALN-AS1-001 (NCT02452372).
started
Oct 1, 2016
primary completion
Nov 5, 2021
completion
Nov 5, 2021
last updated
Mar 12, 2024
official title
A Multicenter, Open-label Extension Study to Evaluate the Long-term Safety and Clinical Activity of Subcutaneously Administered ALN-AS1 in Patients With Acute Intermittent Porphyria Who Have Completed a Previous Clinical Study With ALN-AS1
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol